Orthofix saw single-digit growth in its fourth-quarter and full-year sales in 2025, according to financial results posted Feb. 24.
Seven things to know:
1. Full-year sales were $822.3 million, including sales from the discontinued M6 artificial disc. That’s a 2.9% increase year over year. Excluding M6, full-year net sales grew 4.1% year over year.
2. Global spine sales in 2025 were $677.2 million, a 3.9% increase year over year. Global limb reconstruction sales grew 8.4% year over year with $134.7 million.
3. Spinal implants, biologics and enabling technology sales hit $430 million in 2025, a 2.8% increase year over year. Bone growth therapies were $247.2 million, a 5.9% increase year over year.
4. In the fourth quarter, net sales grew 2% with $219 million, including M6 sales.
5. Orthofix ended the fourth quarter and full year with net losses. Net losses for the fourth quarter were $2.2 million, and full-year net loss was $92.2 million.
6. Orthofix expects 2026 sales to range between $850 million to $860 million, and free cash flow is expected to be positive.
7. Orthofix CEO Massimo Calafiore said in a Feb. 24 news release that 2026 priorities include expanding market penetration and accelerating adoption of enabling technologies.
“With full-year contributions from the TRUELOK Elevate System and the FITBONE Bone Transport and Trochanteric Lengthening Nails, the planned second-half full launch of VIRATA, continued spine commercial channel optimization, a renewed focus on advancing our Biologics portfolio, and sustained momentum across our limb reconstruction and BGT businesses, we believe the company is well-positioned to deliver durable top-line growth, expanding margins, and strong free cash flow that supports long-term shareholder value,” he said.
